- Home
- RSLS vs SNOA Comparison
RSLS vs SNOA Comparison
Compare RSLS & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- SNOA
- Stock Information
- Founded
- RSLS 2002
- SNOA 1999
- Country
- RSLS United States
- SNOA United States
- Employees
- RSLS N/A
- SNOA N/A
- Industry
- RSLS Medical/Dental Instruments
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- SNOA Health Care
- Exchange
- RSLS Nasdaq
- SNOA Nasdaq
- Market Cap
- RSLS 3.2M
- SNOA 3.6M
- IPO Year
- RSLS 2007
- SNOA 2007
- Fundamental
- Price
- RSLS $0.64
- SNOA $3.53
- Analyst Decision
- RSLS Hold
- SNOA
- Analyst Count
- RSLS 1
- SNOA 0
- Target Price
- RSLS N/A
- SNOA N/A
- AVG Volume (30 Days)
- RSLS 3.3M
- SNOA 4.5M
- Earning Date
- RSLS 05-14-2025
- SNOA 02-05-2025
- Dividend Yield
- RSLS N/A
- SNOA N/A
- EPS Growth
- RSLS N/A
- SNOA N/A
- EPS
- RSLS N/A
- SNOA N/A
- Revenue
- RSLS $8,183,000.00
- SNOA $13,973,000.00
- Revenue This Year
- RSLS $17.47
- SNOA $23.89
- Revenue Next Year
- RSLS $20.00
- SNOA $25.45
- P/E Ratio
- RSLS N/A
- SNOA N/A
- Revenue Growth
- RSLS N/A
- SNOA 13.51
- 52 Week Low
- RSLS $0.61
- SNOA $1.90
- 52 Week High
- RSLS $29.00
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- RSLS 19.62
- SNOA 68.09
- Support Level
- RSLS $0.63
- SNOA $2.82
- Resistance Level
- RSLS $1.28
- SNOA $4.46
- Average True Range (ATR)
- RSLS 0.12
- SNOA 0.44
- MACD
- RSLS 0.06
- SNOA 0.15
- Stochastic Oscillator
- RSLS 3.31
- SNOA 63.67
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.